Melanoma
Phio Pharmaceuticals, AgonOx Start Phase I Trial of T-Cell Immunotherapy Combination
The firms will evaluate Phio's self-delivering RNAi compound PH-762 plus AgonOx's autologous tumor-infiltrating lymphocyte therapy in a variety of cancers.
The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.
SkylineDx, NeraCare Partnering on Proteomic Test for Melanoma
The companies inked a codevelopment and licensing agreement for NeraCare's Immunoprint test for identifying high-risk early-stage melanoma patients.
Merck, Moderna's Personalized Vaccine-Keytruda Combo Shines Across Biomarker Subgroups at AACR
Premium
Adding Moderna's vaccine to Merck's checkpoint inhibitor in the adjuvant treatment setting benefited melanoma patients, even across biomarker groups like TMB and PD-L1.
Merck's Keytruda Plus Eisai's Lenvima Fail to Improve Survival in Two Phase III Trials
The trials were designed to evaluate the drug combination in certain patients with advanced melanoma and colorectal cancer.